RxDoctor Payments Data

Carol Nieroda, MD

Emergency Medical Services · Laurel, MDNPI 1649322785

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $665 and has fallen 91.1% since, to $59 in 2025.

$1,315in general payments, 2019–2025

Across 52 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$299
  • Boehringer Ingelheim$212
  • AstraZeneca$172
  • Novo Nordisk$156
  • Amgen$110
  • Biotronik Inc.$109
  • plus $256 from 9 others

What the payments were for

  • Food & beverage$1,315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few emergency medical services providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$69,302
Medicare patients
110
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Potassium Chloride15$5,483
Levetiracetam28$1,893
Levothyroxine Sodium82$1,712
Clonidine13$1,367
Albuterol Sulfate18$1,203
Metoclopramide Hcl12$886
Zolpidem Tartrate30$777
FenofibrateFenofibrate Nanocrystallized17$760
Rosuvastatin Calcium29$738
Atorvastatin Calcium69$660
Pantoprazole Sodium29$563
Valsartan11$471
Escitalopram Oxalate12$427
Omeprazole25$415
Lorazepam18$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$299$8612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few emergency medical services providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other emergency medical services in Laurel

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →